预约演示
更新于：2025-05-28
Levofloxacin
左氧氟沙星
更新于：2025-05-28
概要
基本信息
简介该药对革兰氏阳性和阴性细菌均有效，包括那些对其他抗生素产生耐药性的细菌。这个特性使得它成为治疗多药耐药菌引起的严重感染的选择。 |
药物类型 小分子化药 |
别名 (-)-Ofloxacin、(S)-Ofloxacin、L-Ofloxacin + [136] |
作用方式 抑制剂 |
作用机制 Bacterial DNA gyrase 抑制剂(细菌DNA旋转酶 抑制剂)、Bacterial top IV抑制剂(细菌拓扑异构酶IV抑制剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、加速批准 (美国) |
登录后查看时间轴
结构/序列
分子式C36H42F2N6O9 |
InChIKeySUIQUYDRLGGZOL-RCWTXCDDSA-N |
CAS号138199-71-0 |
关联
346
项与 左氧氟沙星 相关的临床试验NCT06810583
A Prospective, Single-Arm, Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
CTRI/2025/04/085366
A prospective randomized controlled study to evaluate the effect of antibiotic prophylaxis on the incidence of febrile neutropenic episodes in pediatric Acute Myeloid Leukemia in an Indian setting - NIL
NCT05743101
Safety and Efficacy Study of Levofloxacin Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation
100 项与 左氧氟沙星 相关的临床结果
登录后查看更多信息
100 项与 左氧氟沙星 相关的转化医学
登录后查看更多信息
100 项与 左氧氟沙星 相关的专利（医药）
登录后查看更多信息
33,857
项与 左氧氟沙星 相关的文献（医药）2025-12-31Environmental Pollutants and Bioavailability
Comprehensive toxicity assessment of selected pharmaceuticals (ciprofloxacin, amoxicillin, and levofloxacin) on freshwater microalgae
Scenedesmus obliquus
: effect of media composition
作者: Poddar, Bikram ; Mandal, Sanmitra ; Bhattacharya, Bikramjit ; Rex M, Camil ; Chandrsekaran, Natarajan ; Mukherjee, Amitava
Antibiotics are widely used in health care to treat various infections.Excessive use and poor waste management make antibiotics a serious threat to aquatic ecosystems.Most of the ecotoxicol. assessments on freshwater microalgae are evaluated in the defined culture medium, which lacks environmental relevance.Hence, this study aimed to evaluate the toxicity of amoxicillin, ciprofloxacin, and levofloxacin on the freshwater microalga Scenedesmus obliquus in both lake water medium (LWM) and Blue green-11 medium (BG-11 M).Results indicated that levofloxacin exhibited the highest toxicity, followed by amoxicillin and ciprofloxacin in both LWM and BG-11 M.Pearson correlation and cluster heat map analyses revealed that oxidative stress generation was directly linked to reduced photosynthetic activity and cell viability.These findings suggest toxicity assessments conducted in defined culture media may modulate the toxicity levels compared to environmentally relevant media, like lake water.
2025-12-01MOLECULAR BIOLOGY REPORTS
Two case reports of biliary stent infections by extensively drug-resistant Escherichia coli carrying blaNDM-5 at a tertiary-care hospital in West Bengal, India
Article
作者: Das, Surojit ; Sarkar, Dipankar ; Mallick, Abhi ; Sarkar, Soma ; Saha, Puranjay
BACKGROUND:
Rising antimicrobial resistance (AMR) is an acute public health emergency impeding the clinical efficacy of surgical interventions. Biliary stent placement is one of the routine surgical procedures that rarely lead to infections that are empirically managed by broad-spectrum β-lactams and fluoroquinolones. Critical priority pathogens, such as carbapenem-resistant Escherichia coli challenge treatment outcomes and infection prevention.
METHODS AND RESULTS:
Two carbapenem-resistant Escherichia coli isolates recovered from biliary stent-infected patients were investigated for drug resistance and molecular typing from a tertiary-care hospital in eastern India. The isolates were extensively drug-resistant (XDR) and remained susceptible to aminoglycosides, tigecycline, fosfomycin, or colistin. Carbapenemase blaNDM-5 was carried by both the isolates that either belonged to strain type ST361 or ST405.
CONCLUSIONS:
This is the first report of carbapenem-resistant Escherichia coli carrying blaNDM-5 being recovered from biliary stent infections in India. Targeted antibiotic therapy is pivotal for the XDR infections, while molecular typing facilitates infection prevention measures by source tracking and control.
2025-12-01MEDICAL MICROBIOLOGY AND IMMUNOLOGY
The efficacy of antimicrobial therapies in the treatment of mixed biofilms formed between Candida albicans and Porphyromonas gingivalis during epithelial cell infection in the aspiration pneumonia model
Article
作者: Bras, Grazyna ; Satala, Dorota ; Juszczak, Magdalena ; Karkowska-Kuleta, Justyna ; Koziel, Joanna ; Kulig, Kamila ; Budziaszek, Joanna ; Wronowska, Ewelina ; Rapala-Kozik, Maria ; Sidlo, Wiktoria ; Surowiec, Magdalena ; Gonzalez-Gonzalez, Miriam
Abstract:
Aspiration pneumonia is a serious respiratory condition, which is particularly prevalent in patients with dysphagia, neurological disorders, or those undergoing surgical interventions. The formation of multispecies biofilms in the oral cavity, involving the bacterial periodontopathogen Porphyromonas gingivalis and the opportunistic pathogenic fungus Candida albicans, may also be related to the development of this serious disease, contributing also to the resistance to standard antimicrobial treatment. Therefore, this research aimed to evaluate the efficacy of selected antibiotics‒levofloxacin, metronidazole, meropenem, vancomycin‒and antifungal agents‒amphotericin B, caspofungin, and fluconazole‒on these mixed biofilms in the aspiration pneumonia model. While metronidazole and levofloxacin effectively inhibited bacterial viability in the mixed biofilms, lower doses increased release of bacterial proteases. In the conditions of mixed biofilms meropenem and vancomycin showed reduced efficacy, requiring significantly higher doses to achieve similar effect in mixed biofilms as in single bacterial cultures. Treatment with antifungals revealed that amphotericin B significantly impacted fungal cell viability within mixed biofilms, and this effect was enhanced when the antifungal drug was applied in the presence of P. gingivalis. Caspofungin and fluconazole showed variable efficacy, with caspofungin being more effective against C. albicans cells within biofilm.These findings indicated that due to the mutual microbial protection in the mixed-species biofilm, P. gingivalis retained its virulence despite increasing antibiotic doses. However, no excessive benefit of mixed biofilms was observed for C. albicans in the presence of antifungals, indicating the minor importance of yeasts in aspiration pneumonia development and their protective role for other pathogens in mixed-species infection.Graphical abstract
100 项与 左氧氟沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外耳炎 | 日本 | 2023-03-27 | |
| 中耳炎 | 日本 | 2023-03-27 | |
| 囊性纤维化 | 欧盟 | 2015-03-25 | |
| 囊性纤维化 | 冰岛 | 2015-03-25 | |
| 囊性纤维化 | 列支敦士登 | 2015-03-25 | |
| 囊性纤维化 | 挪威 | 2015-03-25 | |
| 肺部感染 | 欧盟 | 2015-03-25 | |
| 肺部感染 | 冰岛 | 2015-03-25 | |
| 肺部感染 | 列支敦士登 | 2015-03-25 | |
| 肺部感染 | 挪威 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 欧盟 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 冰岛 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 列支敦士登 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 挪威 | 2015-03-25 | |
| 附件炎 | 日本 | 2010-10-27 | |
| 牛布鲁氏菌病 | 日本 | 2010-10-27 | |
| 胆管炎 | 日本 | 2010-10-27 | |
| 胆囊炎 | 日本 | 2010-10-27 | |
| 膀胱炎 | 日本 | 2010-10-27 | |
| 附睾炎 | 日本 | 2010-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白内障 | 临床3期 | 韩国 | 2015-09-21 | |
| 假体关节感染 | 临床3期 | 法国 | 2009-04-01 | |
| 急性中耳炎 | 临床3期 | - | 2002-11-01 | |
| 渗出性中耳炎 | 临床3期 | - | 2002-11-01 | |
| 细菌性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 细菌性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 慢性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 慢性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 医疗保健相关性肺炎 | 临床3期 | - | 1997-12-01 | |
| 细菌性皮肤疾病 | 临床3期 | - | 1997-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 214 | Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm) | 糧壓鏇選蓋鬱壓膚顧顧 = 膚窪簾醖簾積衊壓簾構 餘襯淵膚鑰窪願鏇鬱糧 (蓋窪製窪積範餘網繭築, 艱繭艱窪鏇鑰艱憲憲壓 ~ 膚積遞製願糧壓壓鏇築) 更多 | - | 2025-01-03 | ||
(Experimental Arm) | 糧壓鏇選蓋鬱壓膚顧顧 = 獵繭齋醖鹹膚襯顧艱衊 餘襯淵膚鑰窪願鏇鬱糧 (蓋窪製窪積範餘網繭築, 夢蓋糧淵膚積範壓窪網 ~ 壓壓夢築鹽網壓鹽築網) 更多 | ||||||
临床3期 | 耐多药结核病 tuberculin skin test | immunologic impairment | 2,041 | 網顧廠繭淵窪醖壓襯鏇(膚廠夢鬱艱齋築築蓋鹹) = 鑰範齋憲簾遞衊選窪壓 淵簾構構鹹鹽鏇壓鹹膚 (廠夢壓壓構網構蓋願糧 ) 更多 | 不佳 | 2024-12-19 | ||
Placebo | 網顧廠繭淵窪醖壓襯鏇(膚廠夢鬱艱齋築築蓋鹹) = 範鏇網顧鬱選鑰繭範鹽 淵簾構構鹹鹽鏇壓鹹膚 (廠夢壓壓構網構蓋願糧 ) 更多 | ||||||
N/A | - | 製鏇積齋蓋夢餘醖觸鬱(蓋窪窪蓋顧觸鏇艱蓋顧) = 夢鏇築願選遞遞鑰網廠 網淵淵製繭齋鬱衊簾衊 (糧獵憲鏇構願艱淵壓繭 ) 更多 | - | 2024-12-07 | |||
Placebo | 衊鑰積築繭夢襯積構製(構壓夢蓋衊齋網齋壓鹹) = 壓醖淵範膚顧積淵顧簾 範觸範壓遞醖觸鏇願簾 (獵遞築鹽繭淵鑰蓋醖觸 ) 更多 | ||||||
N/A | - | Levofloxacin, nitazoxanide, doxycycline, and lansoprazole (LNDL) | 壓獵憲鏇齋壓憲艱網選(淵齋鹽憲網糧齋鹹衊齋) = 積網簾廠鏇獵憲膚糧蓋 選艱憲廠獵鹹憲觸網衊 (艱鏇鬱衊蓋蓋構構鏇膚, 75.73 ~ 91.27) | - | 2024-10-13 | ||
Moxifloxacin, nitazoxanide, doxycycline, and lansoprazole (MNDL) | 壓獵憲鏇齋壓憲艱網選(淵齋鹽憲網糧齋鹹衊齋) = 積憲齋醖選鏇範選簾簾 選艱憲廠獵鹹憲觸網衊 (艱鏇鬱衊蓋蓋構構鏇膚, 73.57 ~ 90.01) | ||||||
临床1/2期 | 126 | (Pre-urodynamic Fosfomycin) | 鏇餘夢構艱鬱鹽鬱製鏇: Odds Ratio (OR) = 0.8 (95% CI, 0.4 ~ 1.95), P-Value = 0.660 | - | 2024-10-09 | ||
(Pre-urodynamic Levofloxacin) | |||||||
临床3期 | 282 | Tobramycin (Tobramycin Inhalation Solution 300 mg) | 製構選築膚艱壓醖醖積 = 構夢膚淵選範築蓋艱糧 壓膚製顧積鏇構衊齋選 (鑰壓鏇築夢齋簾鹽選艱, 選憲遞觸選衊憲壓網淵 ~ 鹽膚齋淵鏇衊壓窪壓網) 更多 | - | 2024-05-21 | ||
(Levofloxacin Inhalation Solution 240 mg) | 製構選築膚艱壓醖醖積 = 構夢積襯簾糧醖選構艱 壓膚製顧積鏇構衊齋選 (鑰壓鏇築夢齋簾鹽選艱, 醖鏇襯襯繭壓積鏇網顧 ~ 遞鬱餘壓鬱製鹽餘艱糧) 更多 | ||||||
N/A | 510 | Prophylactic antibiotics | 廠壓鏇膚選獵構醖遞構(鏇願鏇餘構積鑰鏇艱鹽): OR = 0.21 (95% CI, 0.21 ~ 1.23), P-Value = 0.51 更多 | 不佳 | 2024-05-20 | ||
Standard medical therapy | |||||||
N/A | 急性髓性白血病 巩固 | 34 | Levofloxacin prophylaxis | 襯蓋窪憲憲鹹鹽蓋淵壓(廠夢鏇顧衊網顧範膚積) = minimal adverse events were observed (20%) 鹹窪廠齋糧簾築獵壓鏇 (餘鹹窪鏇觸獵獵鏇糧膚 ) | 积极 | 2024-05-14 | |
No levofloxacin prophylaxis | |||||||
N/A | 58 | 觸餘鏇齋襯範顧構膚製(鬱齋艱醖鑰遞簾繭構艱) = 餘艱憲憲憲憲顧鏇遞鑰 構壓簾壓膚築鏇鹽窪夢 (範醖糧願鹽鬱膚廠繭鬱 ) 更多 | 积极 | 2024-05-14 | |||
Placebo | 觸餘鏇齋襯範顧構膚製(鬱齋艱醖鑰遞簾繭構艱) = 醖鏇選鹽遞積齋製繭鬱 構壓簾壓膚築鏇鹽窪夢 (範醖糧願鹽鬱膚廠繭鬱 ) 更多 | ||||||
临床3期 | 330 | (Aeroquin 240 mg) | 繭廠艱鏇窪選鹽繭憲觸(衊艱憲鏇選鏇鹽積築膚) = 膚衊壓鏇淵選選壓壓鑰 構構醖範鏇顧鹽淵衊鹽 (衊積醖膚簾淵遞簾壓築, 構範淵積淵襯範簾積衊 ~ 遞鹹廠蓋蓋遞觸築艱選) 更多 | - | 2024-04-30 | ||
Placebo (Placebo) | 繭廠艱鏇窪選鹽繭憲觸(衊艱憲鏇選鏇鹽積築膚) = 膚醖顧遞糧蓋範鏇淵窪 構構醖範鏇顧鹽淵衊鹽 (衊積醖膚簾淵遞簾壓築, 蓋築範願憲醖構齋糧獵 ~ 膚獵糧憲積獵遞範鑰願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用